Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
25 studies found for:    "Splenomegaly"
Show Display Options
RSS Create an RSS feed from your search for:
"Splenomegaly"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Withdrawn Prednisone Plus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly
Conditions: Hyper-reactive Malarial Splenomegaly;   Malaria;   Anaemia
Interventions: Drug: prednisone induction - chloroquine;   Drug: Chloroquine
2 Completed Estimation of Spleen by Residents With VScan
Condition: Splenomegaly
Intervention: Device: VScan Ultrasound (GE Healthcare, USA)
3 Completed Ultrasound Estimation of Spleen Size
Condition: Splenomegaly
Interventions: Device: Vscan Ultrasound (GE Healthcare, USA);   Device: Conventional Ultrasound
4 Completed Spleen Size in Peripheral Blood Stem Cell Donors
Condition: Splenomegaly
Intervention:
5 Recruiting CINC424A2X01B Rollover Protocol
Condition: Splenomegaly
Intervention: Drug: Ruxolitinib
6 Completed
Has Results
Evaluation of a Pocket-Sized Ultrasound Device As an Aid to the Physical Examination
Conditions: Splenomegaly;   Pleural Effusion
Intervention: Device: resident with GE vscan
7 Recruiting The Use of Point-of-Care Ultrasound in the Diagnosis of Acute Infectious Mononucleosis in the Emergency Department
Conditions: Infectious Mononucleosis;   Splenomegaly
Intervention: Device: Point-of-care ultrasound
8 Completed Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly
Condition: Myelofibrosis
Intervention: Drug: SAR302503
9 Not yet recruiting Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia
Conditions: Leukemia;   Myelofibrosis;   Anemia;   Splenomegaly
Interventions: Drug: Rigosertib;   Behavioral: Questionnaire
10 Unknown  Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis
Conditions: Liver Cirrhosis;   Carcinoma, Hepatocellular;   Splenomegaly;   Laparotomy
Intervention:
11 Recruiting The Treatment of Hepatocirrhosis and Portal Hypertension
Condition: Hepatic Cirrhosis
Intervention: Procedure: PSE
12 Completed Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis
Condition: Hematopoietic Neoplasm
Interventions: Drug: SAR302503;   Drug: Placebo
13 Completed Phase 2 Study of SAR302503 in Patients With Myelofibrosis
Condition: Hematopoietic Neoplasm
Intervention: Drug: SAR302503
14 Not yet recruiting Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
Conditions: Anemia;   Fatigue;   Fever;   Lymphadenopathy;   Lymphocytosis;   Night Sweats;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Plasma Cell Myeloma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Plasma Cell Myeloma;   Splenomegaly;   Thrombocytopenia;   Weight Loss
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Metformin Hydrochloride;   Other: Pharmacological Study;   Drug: Ritonavir
15 Active, not recruiting Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Anemia;   Chronic Lymphocytic Leukemia;   Fatigue;   Fever, Sweat, and Hot Flashes;   Hepatomegaly;   Lymphadenopathy;   Lymphocytosis;   Small Lymphocytic Lymphoma;   Splenomegaly;   Thrombocytopenia;   Weight Change
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Biological: Rituximab
16 Completed Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.
Condition: Thalassemia Major
Intervention: Drug: INC424 (ruxolitinib)
17 Unknown  Hemolysis in Patients With Hereditary Spherocytosis (HS)
Conditions: Hereditary;   Hemolysis
Intervention: Other: fermented papaya preparation (FPP)
18 Completed Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome
Conditions: Autoimmune Disease;   Lymphoproliferative Disorder
Intervention: Drug: Fansidar (pyrimethamine and sulfadoxine)
19 Recruiting Natural History of Noncirrhotic Portal Hypertension
Conditions: Cystic Fibrosis;   Immunologic Deficiency Syndrome;   Turner Syndrome;   Congenital Hepatic Fibrosis;   Idiopathic Non-Cirrhotic Portal Hypertension
Intervention:
20 Completed
Has Results
Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS)
Conditions: ALPS;   Hypersplenism;   Lymphadenopathy
Interventions: Drug: Valproic Acid;   Procedure: CT Scan;   Procedure: Blood Sample

   Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.